Arctic Bioscience — Report Publication Announcement 2024

Jun 26, 2024

Arctic Bioscience - New positive data showing anti-inflammatory effects of phospholipid esters from herring roe in immune cells

Arctic Bioscience - New positive data showing anti-inflammatory effects of phospholipid esters from herring roe in immune cells

Arctic Bioscience are today presenting a new data on anti-inflammatory cellular

functions of herring roe oil at the 9th European Workshop on Lipid Mediators in

Edinburgh, UK.

"We are very pleased to announce new positive data on the anti-inflammatory

properties related to our investigational medicine, HRO350. The data show an

effect on cells which may also have benefit in other inflammatory diseases,

which we will explore further", says CEO Christer L. Valderhaug.

"These data are important because they illuminate a mechanism of action of

HRO350, which is currently being tested in a phase 2b clinical trial for mild-to

-moderate psoriasis. Scientifically, this is state-of-the-art lipidomics, and we

have collaborated with a key international research group in this field. We are

also proud that this research has been conducted in Norway, with cellular

researchers at Møreforsking", says Medical Director Runhild Gammelsæter.

The HeROPA clinical trial on HRO350 with the active substance Phospholipid

Esters from Herring Roe (PeHeRo) is ongoing in mild-to-moderate psoriasis, with

planned read-out fall 2024.

These new data on human primary immune cells show that Phospholipid Esters from

Herring Roe promotes biosynthesis of specialized pro-resolving mediators (SPMs)

that are involved in anti-inflammatory activities. This mode of action can be a

promising treatment modality in inflammatory conditions, including psoriasis,

and supports an anti-inflammatory action of the investigational medicinal

product HRO350. These data support previously published effects on inflammatory

markers in psoriasis (Petrovic 2023).

"Our chemists in the R&D department have been working on this research project

for three years, and we are very excited to see the effects of the extracts we

have developed in our lab", says CTO Daniele Mancinelli.

The study was conducted in collaboration with Møreforsking and was supported

with a grant from the Norwegian Research Council (project nr. 327953, Properties

of phospholipids from Herring Roe in Psoriasis).

Reference: Ringheim-Bakka T, Mildenberger J, Dalli J, Saliani A, Petrucelli F,

Busygina M, Mancinelli D, Gammelsæter R. "Phospholipid Esters from Herring Roe

promotes SPM biosynthesis in human monocyte-derived macrophages with

implications for the treatment of psoriasis". Poster at the 9th European

Workshop on Lipid Mediators, June 26-28th, 2024.

The poster will be made available on the IR tab on the company's webpage.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

Email: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.